Y549 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¹«±â¿°·ù | Mineral salts, NEC causing adverse effects in therapeutic use |
 |
Y55 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÆòȰ±Ù ¹× °ñ°Ý±Ù°ú È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily acting on smooth and skeletal muscles and the respiratory system causing adverse effects in therapeutic use |
 |
Y550 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀڱüöÃ༺ ¾à¹° | Oxytocic drugs causing adverse effects in therapeutic use |
 |
Y550 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸Æ°¢¾ËÄ®·ÎÀ̵å | Ergot alkaloids causing adverse effects in therapeutic use |
 |
Y551 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °ñ°Ý±ÙÀÌ¿ÏÁ¦[½Å°æ±ÙÀ° Â÷´ÜÁ¦] | Skeletal muscle relaxants [neuromusclular blocking agents]causing adverse effects in therapeutic use |
 |
Y552 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ±ÙÀ°¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ | Other and unspecified agents primarily acting on muscles causing adverse effects in therapeutic use |
 |
Y553 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âħ¾à | Antitussives causing adverse effects in therapeutic use |
 |
Y554 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¡·¡¾à | Expectorants causing adverse effects in therapeutic use |
 |
Y555 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¨±â¾à | Anti-common-cold drugs causing adverse effects in therapeutic use |
 |
Y556 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×õ½ÄÁ¦ | Antiasthmatics, NEC causing adverse effects in therapeutic use |
 |
Y556 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¹Ì³ëÇʸ° | Aminophylline causing adverse effects in therapeutic use |
 |
Y556 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ìºÎŸ¸ô | Salbutamol causing adverse effects in therapeutic use |
 |
Y556 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ƽ¿ÀºÎ·Î¹Î | Theobromine causing adverse effects in therapeutic use |
 |
Y556 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å׿ÀÇʸ° | Theophylline causing adverse effects in therapeutic use |
 |
Y557 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ | Other and unspecified agents primarily acting on the respiratory system causing adverse effects in therapeutic use |
 |
Y56 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÇǺΠ¹× Á¡¸·¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦¿Í ¾È°úÀû, À̺ñÀÎÈİúÀû ¹× Ä¡°úÀû Á¦Á¦ | Agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs causing adverse effects in therapeutic use |
 |
Y56 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼ÒÀûÀ¸·Î »ç¿ëµÈ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å | Glucocorticoids, topically used causing adverse effects in therapeutic use |
 |
Y560 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±¹¼Ò Ç×Áø±ÕÁ¦, Ç×°¨¿°Á¦ ¹× Ç׿°ÁõÁ¦ | Local antifungal, anti-infective and anti-inflammatory drugs, NEC causing adverse effects in therapeutic use |
 |
Y561 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°¡·Á¿òÁ¦ | Antipruritics causing adverse effects in therapeutic use |
 |
Y562 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼Ò¼ö·ÅÁ¦ ¹× ±¹¼Ò¼¼Á¤Á¦ | Local astringents and local detergents causing adverse effects in therapeutic use |
 |